https://www.selleckchem.com/pr....oducts/elacestrant.h
The remission rate in children with Graves' disease (GD) after 2-6 years of antithyroid drug (ATD) treatment is 40-50%. It has been reported that it is difficult to predict the GD prognosis based on the TSH receptor antibody (TRAb) level at the cessation of ATD treatment. We studied whether the persistence of negative TRAb at ATD treatment cessation increased the remission rate in pediatric patients with GD. We included 22 patients diagnosed with GD who discontinued ATD treatment after confirmation of negative TRAb on two or more co